BACKGROUND: The reproductive implications of mutagenic treatments given to children with cancer are not clear. By studying the risk of untoward pregnancy outcomes, we indirectly assessed the risk of transmission of germline damage to the offspring of survivors of childhood cancer who were given radiotherapy and chemotherapy. METHODS: We did a retrospective cohort analysis, within the Childhood Cancer Survivor Study (CCSS), of the risk of stillbirth and neonatal death among the offspring of men and women who had survived childhood cancer. Patients in CCSS were younger than 21 years at initial diagnosis of an eligible cancer, were treated at 25 US institutions and one Canadian institution, and had survived for at least 5 years after diagnosis. We quantified the chemotherapy given to patients, and the preconception radiation doses to the testes, ovaries, uterus, and pituitary gland, and related these to the risk of stillbirth or neonatal death using Poisson regression analysis. FINDINGS: Among 1148 men and 1657 women who had survived childhood cancer, there were 4946 pregnancies. Irradiation of the testes (16 [1%] of 1270; adjusted relative risk 0.8 [95% CI 0.4-1.6]; mean dose 0.53 Gy [SD 1.40]) and pituitary gland (17 [3%] of 510, 1.1 [0.5-2.4] for more than 20.00 Gy; mean dose 10.20 Gy [13.0] for women), and chemotherapy with alkylating drugs (26 [2%] of 1195 women, 0.9 [0.5-1.5]; ten [1%] of 732 men, 1.2 [0.5-2.5]) were not associated with an increased risk of stillbirth or neonatal death. Uterine and ovarian irradiation significantly increased risk of stillbirth and neonatal death at doses greater than 10.00 Gy (five [18%] of 28, 9.1 [3.4-24.6]). For girls treated before menarche, irradiation of the uterus and ovaries at doses as low as 1.00-2.49 Gy significantly increased the risk of stillbirth or neonatal death (three [4%] of 69, 4.7 [1.2-19.0]). INTERPRETATION: Our findings do not support concern about heritable genetic changes affecting the risk of stillbirth and neonatal death in the offspring of men exposed to gonadal irradiation. However, uterine and ovarian irradiation had serious adverse effects on the offspring that were probably related to uterine damage. Careful management is warranted of pregnancies in women given high doses of pelvic irradiation before puberty. FUNDING: Westlakes Research Institute, National Cancer Institute, and Children's Cancer Research Fund. Copyright 2010 Elsevier Ltd. All rights reserved.
BACKGROUND: The reproductive implications of mutagenic treatments given to children with cancer are not clear. By studying the risk of untoward pregnancy outcomes, we indirectly assessed the risk of transmission of germline damage to the offspring of survivors of childhood cancer who were given radiotherapy and chemotherapy. METHODS: We did a retrospective cohort analysis, within the Childhood Cancer Survivor Study (CCSS), of the risk of stillbirth and neonatal death among the offspring of men and women who had survived childhood cancer. Patients in CCSS were younger than 21 years at initial diagnosis of an eligible cancer, were treated at 25 US institutions and one Canadian institution, and had survived for at least 5 years after diagnosis. We quantified the chemotherapy given to patients, and the preconception radiation doses to the testes, ovaries, uterus, and pituitary gland, and related these to the risk of stillbirth or neonatal death using Poisson regression analysis. FINDINGS: Among 1148 men and 1657 women who had survived childhood cancer, there were 4946 pregnancies. Irradiation of the testes (16 [1%] of 1270; adjusted relative risk 0.8 [95% CI 0.4-1.6]; mean dose 0.53 Gy [SD 1.40]) and pituitary gland (17 [3%] of 510, 1.1 [0.5-2.4] for more than 20.00 Gy; mean dose 10.20 Gy [13.0] for women), and chemotherapy with alkylating drugs (26 [2%] of 1195 women, 0.9 [0.5-1.5]; ten [1%] of 732 men, 1.2 [0.5-2.5]) were not associated with an increased risk of stillbirth or neonatal death. Uterine and ovarian irradiation significantly increased risk of stillbirth and neonatal death at doses greater than 10.00 Gy (five [18%] of 28, 9.1 [3.4-24.6]). For girls treated before menarche, irradiation of the uterus and ovaries at doses as low as 1.00-2.49 Gy significantly increased the risk of stillbirth or neonatal death (three [4%] of 69, 4.7 [1.2-19.0]). INTERPRETATION: Our findings do not support concern about heritable genetic changes affecting the risk of stillbirth and neonatal death in the offspring of men exposed to gonadal irradiation. However, uterine and ovarian irradiation had serious adverse effects on the offspring that were probably related to uterine damage. Careful management is warranted of pregnancies in women given high doses of pelvic irradiation before puberty. FUNDING: Westlakes Research Institute, National Cancer Institute, and Children's Cancer Research Fund. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: Jeanette Falck Winther; John D Boice; John J Mulvihill; Marilyn Stovall; Kirsten Frederiksen; E Janet Tawn; Jorgen H Olsen Journal: Am J Hum Genet Date: 2004-04-21 Impact factor: 11.025
Authors: Marilyn Stovall; Sarah S Donaldson; Rita E Weathers; Leslie L Robison; Ann C Mertens; Jeanette Falck Winther; Jorgen H Olsen; John D Boice Journal: Int J Radiat Oncol Biol Phys Date: 2004-10-01 Impact factor: 8.013
Authors: John D Boice; E Janet Tawn; Jeanette F Winther; Sarah S Donaldson; Daniel M Green; Ann C Mertens; John J Mulvihill; Jørgen H Olsen; Leslie L Robison; Marilyn Stovall Journal: Health Phys Date: 2003-07 Impact factor: 2.922
Authors: Lisa B Signorello; John J Mulvihill; Daniel M Green; Heather M Munro; Marilyn Stovall; Rita E Weathers; Ann C Mertens; John A Whitton; Leslie L Robison; John D Boice Journal: J Clin Oncol Date: 2011-12-12 Impact factor: 44.544
Authors: Alexandra S Rashedi; Saskia F de Roo; Lauren M Ataman; Maxwell E Edmonds; Adelino Amaral Silva; Anibal Scarella; Anna Horbaczewska; Antoinette Anazodo; Ayse Arvas; Bruno Ramalho de Carvalho; Cassio Sartorio; Catharina C M Beerendonk; Cesar Diaz-Garcia; Chang Suk Suh; Cláudia Melo; Claus Yding Andersen; Eduardo Motta; Ellen M Greenblatt; Ellen Van Moer; Elnaz Zand; Fernando M Reis; Flor Sánchez; Guillermo Terrado; Jhenifer K Rodrigues; Joao Marcos de Meneses E Silva; Johan Smitz; Jose Medrano; Jung Ryeol Lee; Katharina Winkler-Crepaz; Kristin Smith; Lígia Helena Ferreira Melo E Silva; Ludwig Wildt; Mahmoud Salama; María Del Mar Andrés; Maria T Bourlon; Mario Vega; Maurício Barbour Chehin; Michel De Vos; Mohamed Khrouf; Nao Suzuki; Osama Azmy; Paula Fontoura; Paulo Henrique Almeida Campos-Junior; Peter Mallmann; Ricardo Azambuja; Ricardo M Marinho; Richard A Anderson; Robert Jach; Roberto de A Antunes; Rod Mitchell; Rouhollah Fathi; Satish Kumar Adiga; Seido Takae; Seok Hyun Kim; Sergio Romero; Silvana Chedid Grieco; Talya Shaulov; Tatsuro Furui; Teresa Almeida-Santos; Willianne Nelen; Yasmin Jayasinghe; Yodo Sugishita; Teresa K Woodruff Journal: J Glob Oncol Date: 2017-06-30
Authors: Ruba A Akel; Xiaoyue M Guo; Molly B Moravek; Rafael Confino; Kristin N Smith; Angela K Lawson; Susan C Klock; Edward J Tanner Iii; Mary Ellen Pavone Journal: J Adolesc Young Adult Oncol Date: 2020-01-10 Impact factor: 2.223
Authors: Prasad L Gawade; Kevin C Oeffinger; Charles A Sklar; Daniel M Green; Kevin R Krull; Wassim Chemaitilly; Marilyn Stovall; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Kirsten K Ness Journal: Am J Obstet Gynecol Date: 2014-07-25 Impact factor: 8.661